Sempra (SRE) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
16 Jan, 2026Executive summary
Q3 2024 adjusted EPS was $0.89 and GAAP EPS was $1.00, with year-to-date adjusted EPS of $3.12 and GAAP EPS of $3.38; both declined year-over-year.
Full-year 2024 and 2025 adjusted EPS guidance reaffirmed at $4.60–$4.90 and $4.90–$5.25, with a projected long-term EPS growth rate of 6%-8%.
Major growth drivers include robust capital investment opportunities in Texas and California, especially in high-voltage transmission and LNG infrastructure.
Pending California GRC decision will retroactively impact 2024 earnings once finalized.
Disciplined growth strategy focuses on modern energy networks, safety, reliability, and clean energy transition.
Financial highlights
Q3 2024 GAAP earnings were $638M ($1.00/share), down from $721M ($1.14/share) in Q3 2023; adjusted earnings were $566M ($0.89/share), down from $685M ($1.08/share).
Nine-month 2024 GAAP earnings were $2.152B ($3.38/share), adjusted earnings $1.987B ($3.12/share), both down year-over-year.
Q3 2024 revenues were $4.798B, down from $7.560B in Q3 2023; YTD revenues were $9.427B, down from $13.229B.
Operating cash flow for the first nine months was $3.54B, down from $5.13B in 2023.
Capital expenditures and investments YTD totaled $6.35B, flat year-over-year.
Outlook and guidance
Full-year 2024 and 2025 adjusted EPS guidance and long-term EPS growth rate are reaffirmed; 2024 GAAP EPS guidance updated to $4.86–$5.16.
Management is confident in delivering or exceeding the 6%-8% EPS CAGR, citing a strong backlog of growth opportunities.
$3B at-the-market equity program established to fund capital expenditures and maintain balance sheet strength.
Oncor's five-year capital plan expected to increase 40%-50% due to strong load growth and new investment opportunities.
Updated five-year capital plan and 2026 guidance to be provided in February.
Latest events from Sempra
- $65B capital plan and record adjusted EPS drive sector-leading growth outlook.SRE
Q4 202526 Feb 2026 - Q2 2024 earnings rose to $713M, with strong Texas/California growth and major projects advancing.SRE
Q2 20242 Feb 2026 - Q1 2025 EPS up, guidance affirmed, and major asset sales and capital investment drive outlook.SRE
Q1 20258 Jan 2026 - 2024 adjusted EPS hit $4.65, with a $56B capital plan and 7–9% EPS growth targeted.SRE
Q4 20247 Jan 2026 - Board refreshment, performance-based pay, and ambitious ESG targets headline the 2025 proxy.SRE
Proxy Filing1 Dec 2025 - Director nominee Jennifer M. Kirk will become CEO of Exubrion Therapeutics in May 2025.SRE
Proxy Filing1 Dec 2025 - Virtual meeting to elect 11 directors, ratify auditor, and approve executive pay.SRE
Proxy Filing1 Dec 2025 - Q2 2025 adjusted EPS held steady as utility growth, LNG progress, and guidance advanced.SRE
Q2 202523 Nov 2025 - Adjusted EPS up, major asset sale and Texas/LNG growth drive strong long-term outlook.SRE
Q3 20255 Nov 2025